Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc.

Bullboard Posts

Comment by Maceron Aug 02, 2019 8:50pm

115 Views

Post# 29990909

RE:RE:RE:Glad the market is discounting the Offering unit price

skier59 wrote: enriquesuave I'm so glad there are a few intelligent posters like you on this comedy board.

enriquesuave wrote: Ideally they fill maximum $8 Million as that would basically be like filling $17.7 million at 0.325 warrants included. That would cover entire PH2 trial and another PH1 for another indication. They already have $2 million for working capital for the next 12 months. IMHO When preliminary data comes out all, if as good as PH1, other warrants at 0.375 and 0.50 could be converted adding another $15 Million . That would cover a 3rd PH1 and FDA NDA after Accelerated approval IMhO. The PH1 for other indications could simply be used to show proof of concept that Rutherrin is hopefully safe and shows promising exploratory efficacy in humans for GBM, NSCLC and others. Once we show Gold Standard Potential for NMIBC, the other indications will just bring up the BO value to above $10 Billion. All IMHO. Seen it done before , KITE, Actellion etc. Hopefully we get the same valuation or more in due time. No reason not to if data is stellar as in PH1 IMO.

newdaydawning wrote: Hopefully the current downtick will continue, creating resistance for would-be participants in the offering.

I hope the money raise falls short of the minimum target. Assuming that we stick to our knitting in Canada and get four sites rolled out, we would only need about $5M to get to meaningful clinical results. If we replicate Ph1b outcomes, the warrants would get us to the next financing, well north of 50 cents.

Hoping the selling continues. Will continue to add if we plumb below 25 cents.